Literature DB >> 32677118

Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.

Shaunna L Beedie1,2, Phoebe A Huang1, Emily M Harris1, Jonathan D Strope1, Christopher Mahony2, Cindy H Chau1, Neil Vargesson2, William D Figg1.   

Abstract

Cereblon (CRBN) is a substrate recruiter element of the E3 cullin 4-RING ubiquitin ligase complex, and a binding target of immunomodulatory agents (IMiDs). CRBN is responsible for the pleiotropic effects of IMiDs, yet its function in angiogenesis and in mediating the antiangiogenic effects of IMiDs remains unclear. We investigated the role of CRBN in the angiogenic process and in propagating the antiangiogenic effects of IMiDs in vitro. siRNA-mediated CRBN knock down in human endothelial cells (HUVEC and HMVEC-L), did not affect endothelial cell proliferation, migration, or tube formation. Using CRBN-deficient mice, we further demonstrated that microvessal formation can occur independently of cereblon in the ex vivo mouse aortic ring model. The cereblon E3 ubiquitin ligase complex can recruit endothelial cell-specific factors, AGO2 (associated with angiogenesis), and SALL4 (associated with embryogenesis/angiogenesis), for ubiquitin-mediated degradation. Knockdown of CRBN caused a corresponding increase in AGO2 and SALL4 protein expression and IMiD treatment was able to rescue the siCRBN effect to increase the CRBN expression. These findings suggest one potential mechanism of action that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which IMiDs exert their antiangiogenic effects.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  SALL4; angiogenesis; argonaute-2; cereblon; endothelial cell; immunomodulatory drugs

Mesh:

Substances:

Year:  2020        PMID: 32677118      PMCID: PMC8819519          DOI: 10.1096/fj.201903060RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  39 in total

1.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.

Authors:  Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

2.  siRNA knockdown of gene expression in endothelial cells.

Authors:  Emily Dennstedt; Brad Bryan
Journal:  Methods Mol Biol       Date:  2011

3.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

4.  Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Yasuhiro Kazuki; Ken Oofusa; Shunji Kuribayashi; Makiko Shimizu; Shinichi Ninomiya; Toru Horie; Norio Shibata; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-29       Impact factor: 3.739

5.  Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.

Authors:  Christina Therapontos; Lynda Erskine; Erin R Gardner; William D Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

6.  CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos.

Authors:  Chris Mahony; Scott McMenemy; Alexandra J Rafipay; Shaunna-Leigh Beedie; Lucas Rosa Fraga; Michael Gütschow; William D Figg; Lynda Erskine; Neil Vargesson
Journal:  J Anat       Date:  2017-10-10       Impact factor: 2.610

7.  p63 is a cereblon substrate involved in thalidomide teratogenicity.

Authors:  Tomoko Asatsuma-Okumura; Hideki Ando; Marco De Simone; Junichi Yamamoto; Tomomi Sato; Nobuyuki Shimizu; Kazuhide Asakawa; Yuki Yamaguchi; Takumi Ito; Luisa Guerrini; Hiroshi Handa
Journal:  Nat Chem Biol       Date:  2019-10-07       Impact factor: 15.040

8.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors:  A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

9.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

10.  Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation.

Authors:  Shuang Wu; Wenjun Yu; Xiaoyan Qu; Rong Wang; Ji Xu; Qiguo Zhang; Jiaren Xu; Jianyong Li; Lijuan Chen
Journal:  J Hematol Oncol       Date:  2014-05-07       Impact factor: 17.388

View more
  4 in total

1.  On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.

Authors:  Christopher Heim; Samuel Maiwald; Christian Steinebach; Matthew K Collins; Jonathan Strope; Cindy H Chau; William D Figg; Michael Gütschow; Marcus D Hartmann
Journal:  Biochem Biophys Res Commun       Date:  2020-12-10       Impact factor: 3.575

2.  Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs.

Authors:  Megan L Peach; Shaunna L Beedie; Cindy H Chau; Matthew K Collins; Suzana Markolovic; Weiming Luo; David Tweedie; Christian Steinebach; Nigel H Greig; Michael Gütschow; Neil Vargesson; Marc C Nicklaus; William D Figg
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

3.  Comparative Genomics Identifies Putative Interspecies Mechanisms Underlying Crbn-Sall4-Linked Thalidomide Embryopathy.

Authors:  Thayne Woycinck Kowalski; Gabriela Barreto Caldas-Garcia; Julia do Amaral Gomes; Lucas Rosa Fraga; Lavínia Schuler-Faccini; Mariana Recamonde-Mendoza; Vanessa Rodrigues Paixão-Côrtes; Fernanda Sales Luiz Vianna
Journal:  Front Genet       Date:  2021-06-23       Impact factor: 4.599

Review 4.  From the Farm to the Lab: How Chicken Embryos Contribute to the Field of Teratology.

Authors:  Gabriela Elis Wachholz; Bruna Duarte Rengel; Neil Vargesson; Lucas Rosa Fraga
Journal:  Front Genet       Date:  2021-07-22       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.